Wall Street analysts expect Johnson & Johnson (NYSE:JNJ) to post sales of $19.26 billion for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Johnson & Johnson’s earnings, with the lowest sales estimate coming in at $19.13 billion and the highest estimate coming in at $19.39 billion. Johnson & Johnson reported sales of $17.82 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 8.1%. The firm is scheduled to issue its next earnings report before the market opens on Tuesday, October 17th.

According to Zacks, analysts expect that Johnson & Johnson will report full-year sales of $19.26 billion for the current year, with estimates ranging from $75.79 billion to $76.22 billion. For the next year, analysts forecast that the business will post sales of $80.08 billion per share, with estimates ranging from $79.40 billion to $81.04 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that cover Johnson & Johnson.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The business’s revenue was up 1.9% compared to the same quarter last year. During the same period last year, the company earned $1.74 earnings per share.

Several research analysts have recently commented on JNJ shares. Cowen and Company reaffirmed an “outperform” rating and set a $143.00 target price on shares of Johnson & Johnson in a report on Tuesday, June 13th. Royal Bank Of Canada reiterated a “buy” rating and set a $128.00 price target on shares of Johnson & Johnson in a research report on Thursday, June 15th. Jefferies Group LLC reiterated a “hold” rating and set a $140.00 price target on shares of Johnson & Johnson in a research report on Friday, June 16th. BidaskClub upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Finally, Morgan Stanley raised their target price on shares of Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, July 5th. Five analysts have rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $134.79.

ILLEGAL ACTIVITY WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/johnson-johnson-jnj-expected-to-post-quarterly-sales-of-19-26-billion/1611233.html.

In other news, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the sale, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the sale, the vice president now directly owns 226,693 shares in the company, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Lenox Wealth Advisors Inc. lifted its holdings in Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares in the last quarter. Landmark Financial Advisors LLC raised its position in shares of Johnson & Johnson by 0.4% during the second quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock valued at $259,000 after buying an additional 7 shares during the last quarter. Paradigm Financial Advisors LLC raised its position in shares of Johnson & Johnson by 0.3% during the second quarter. Paradigm Financial Advisors LLC now owns 2,649 shares of the company’s stock valued at $350,000 after buying an additional 9 shares during the last quarter. Premier Asset Management LLC raised its position in shares of Johnson & Johnson by 0.4% during the second quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock valued at $363,000 after buying an additional 12 shares during the last quarter. Finally, Lbmc Investment Advisors LLC raised its position in shares of Johnson & Johnson by 0.4% during the first quarter. Lbmc Investment Advisors LLC now owns 3,704 shares of the company’s stock valued at $461,000 after buying an additional 14 shares during the last quarter. 65.90% of the stock is currently owned by institutional investors.

Johnson & Johnson (JNJ) traded up 0.23% during trading on Monday, hitting $133.19. The stock had a trading volume of 3,741,108 shares. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08. The stock has a 50 day moving average price of $132.23 and a 200 day moving average price of $129.83. The company has a market capitalization of $357.48 billion, a price-to-earnings ratio of 22.54 and a beta of 0.78.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were paid a dividend of $0.84 per share. The ex-dividend date was Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a yield of 2.52%. Johnson & Johnson’s dividend payout ratio is currently 56.76%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.